Prothena Announces Departure of Chief Medical Officer
02 févr. 2018 16h15 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14
01 févr. 2018 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference
03 janv. 2018 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Participate in the Evercore ISI Biopharma Catalyst/Deep Dive Conference
22 nov. 2017 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Highlights Breadth of Novel Pipeline at R&D Day
16 nov. 2017 08h00 HE
|
Prothena Corporation plc
Clinical development programs advancing toward key milestonesDr. Morie Gertz of Mayo Clinic discusses clinical aspects of AL amyloidosis and the role of cardiac biomarker NT-proBNPNovel discovery...
Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update
07 nov. 2017 16h05 HE
|
Prothena Corporation plc
Net cash used in operating and investing activities was $18.3 million in the third quarter and $94.8 million for the first nine months of 2017; quarter-end cash and restricted cash position of $460.1...
Prothena to Participate in the Credit Suisse 26th Annual Healthcare Conference
01 nov. 2017 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Report Third Quarter 2017 Financial Results on November 7
31 oct. 2017 16h05 HE
|
Prothena Corporation plc
DUBLIN, Ireland, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports Results from Phase 1b Multiple Ascending Dose Study of PRX003 in Patients with Psoriasis
28 sept. 2017 16h05 HE
|
Prothena Corporation Plc
Data demonstrated consistent safety, tolerability and pharmacodynamic effects as previously reported from Phase 1a single ascending dose (SAD) studyObserved clinical efficacy and reductions in markers...
Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis
18 sept. 2017 08h00 HE
|
Prothena Corporation Plc
Preclinical Research Demonstrating a Direct Relationship Between Misfolded Light Chain Toxicity and NT-proBNP ProductionClinical Outcomes Research Showing a Correlation between NT-proBNP Response and...